flagyl 5 mg/ ml
sanofi-aventis norge (3) - metronidazolbenzoat - infusjonsvæske, oppløsning - 5 mg/ ml
flagyl 400 mg
sanofi-aventis norge (3) - metronidazol - tablett, filmdrasjert - 400 mg
flagyl 500 mg
sanofi-aventis norge (3) - metronidazol - vagitorie - 500 mg
metronidazol actavis 500 mg
actavis group ptc ehf (1) - metronidazol - tablett, filmdrasjert - 500 mg
metronidazol baxter viaflo 5 mg/ ml
baxter medical ab - metronidazol - infusjonsvæske, oppløsning - 5 mg/ ml
accusol 35
nikkiso belgium bvba - kalsiumkloriddihydrat / magnesiumkloridheksahydrat / natriumklorid / natriumhydrogenkarbonat - hemofiltrerings-, hemodialyse- og hemodiafiltreringsvæske - 0.257 g/ l / 0.102 g/ l / 6.14 g/ l / 2.94 g/ l
accusol 35 kalium 2 mmol/l
nikkiso belgium bvba - kalsiumkloriddihydrat / magnesiumkloridheksahydrat / natriumklorid / kaliumklorid / glukose / natriumhydrogenkarbonat - hemofiltrerings-, hemodialyse- og hemodiafiltreringsvæske
accusol 35 kalium 4 mmol/l
nikkiso belgium bvba - kalsiumkloriddihydrat / magnesiumkloridheksahydrat / natriumklorid / kaliumklorid / glukose / natriumhydrogenkarbonat - hemofiltrerings-, hemodialyse- og hemodiafiltreringsvæske
azacitidine mylan
mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.
removab
neovii biotech gmbh - catumaxomab - ascites; cancer - andre antineoplastiske midler - removab er indisert for intraperitoneal behandling av ondartet ascites hos pasienter med epcam-positive karcinomer der standardbehandling ikke er tilgjengelig eller ikke lenger mulig.